Severe/Very Severe COVID-19 Illness
2 clinical trials · Condition
◉ Watch Severe/Very Severe COVID-19 Illness
| Record | Firm | Date |
|---|---|---|
| Ruxolitinib Managed Access Program (MAP) for Patients Diagnosed With Severe/Very Severe COVID-19 Illness (NCT04337359) | Novartis Pharmaceuticals | |
| Managed Access Programs for INC424, Ruxolitinib (NCT04745637) | Novartis Pharmaceuticals |
Track Severe/Very Severe COVID-19 Illness automatically
Every clearance here is in the API, with alerts when new ones post.